.Attributes Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of patients with HER2+ enhanced bosom cancer cells as well as energetic or even steady brain metastases revealed consistent intracranial task and systemic efficiency of T-DXd.